EGR3 and neoplasm: In addition to studying the over-expression of Egr3, we also used the extensive prostate gene expression datasets from the University of California-Irvine SPECS program to examine the expression pattern of Egr3 in prostate cancer patients with known relapse status, and found that Egr3 expression in tumor cells is lower in tumors that relapse compared to tumors that do not relapse.